Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial

被引：0

作者：

D'Agostino, Mattia ^{[1
,2
]}

Antonioli, Elisabetta ^{[3
]}

Gamberi, Barbara ^{[4
]}

Bruno, Benedetto ^{[1
,2
]}

Derudas, Daniele ^{[5
]}

Tosi, Patrizia ^{[6
]}

Fazio, Francesca ^{[7
]}

Carlo-Stella, Carmelo ^{[8
,9
]}

Ronconi, Sonia ^{[10
]}

Corradini, Paolo ^{[11
]}

Ballanti, Stelvio ^{[12
]}

Cellini, Claudia ^{[13
]}

Falcone, Antonietta Pia ^{[14
]}

Bringhen, Sara ^{[15
]}

Offidani, Massimo ^{[16
]}

Rambaldi, Alessandro ^{[17
]}

Rota-Scalabrini, Delia ^{[18
]}

Agazzi, Alberto ^{[19
]}

Casaluci, Gloria Margiotta ^{[20
]}

Pietrantuono, Giuseppe ^{[21
]}

Patriarca, Francesca ^{[22
,23
]}

Larocca, Alessandra ^{[2
,15
]}

Boccadoro, Mario ^{[24
]}

机构：

[1] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[2] Univ Torino, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy

[3] AOU Careggi, UO Ematol, Florence, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] ARNAS G Brozu, Osped Oncol Riferimento Reg A Businco, SC Ematol & CTMO, Cagliari, Italy

[6] Osped Rimini, UO Ematol, Rimini, Italy

[7] Sapienza Univ Rome, Dept Translat & Precis Med, Hematol, Rome, Italy

[8] Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy

[9] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

[10] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Meldola, Italy

[11] Fdn IRCCS Ist Nazl Tumori, Milan, MI, Italy

[12] Osped Santa Maria Misericordia, Sez Ematol & Immunol Clin, Localita St Andrea Fratte, Perugia, Italy

[13] Osped Santa Maria Croci, UOC Ematol, AUSL Romagna, Ravenna, Italy

[14] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol, San Giovanni Rotondo, Italy

[15] Azienda Osped Univ Citta Salute & Sci Torino, Dept Oncol, SSD Clin Trial Oncoematol & Mieloma Multiplo, Turin, Italy

[16] Azienda Osped Univ Marche, Clin Ematol, Ancona, Italy

[17] ASST Papa Giovanni XXIII, UO Ematol, Bergamo, Italy

[18] FPO IRCCS, Candiolo Canc Inst, Dept Med Oncol, Turin, Italy

[19] European Inst Oncol, Hematoncol Div, Milan, Italy

[20] AOU Maggiore Carita, Novara, Italy

[21] IRCCS Ctr Riferimento Oncol Basilicata, Hematol & Stem Cell Transplantat Unit, Rionero In Vulture, Italy

[22] Univ Udine, Dipartimento Area Med DAME, ASUFC, Clin Ematol, Udine, Italy

[23] Univ Udine, Unita Terapie Cellulari, ASUFC, Clin Ematol, Udine, Italy

[24] European Myeloma Network, Milan, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-109

引用

页码：S94 / S95

页数：2

共 50 条

[1] Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
Dimopoulos, M. A.
Stewart, A. K.
Masszi, T.
Spicka, I.
Oriol, A.
Hajek, R.
Rosinol, L.
Siegel, D.
Mihaylov, G. G.
Goranova-Marinova, V.
Rajnics, P.
Suvorov, A.
Niesvizky, R.
Jakubowiak, A.
San-Miguel, J.
Ludwig, H.
Ro, S.
Aggarwal, S.
Moreau, P.
Palumbo, A.
BLOOD CANCER JOURNAL, 2017, 7 : e554 - e554
[2] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Facon, Thierry
Venner, Christopher P.
Bahlis, Nizar J.
Offner, Fritz
White, Darrell J.
Karlin, Lionel
Benboubker, Lotfi
Rigaudeau, Sophie
Rodon, Philippe
Voog, Eric
Yoon, Sung-Soo
Suzuki, Kenshi
Shibayama, Hirohiko
Zhang, Xiaoquan
Twumasi-Ankrah, Philip
Yung, Godwin
Rifkin, Robert M.
Moreau, Philippe
Lonial, Sagar
Kumar, Shaji K.
Richardson, Paul G.
Rajkumar, S. Vincent
BLOOD, 2021, 137 (26) : 3616 - 3628
[3] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Korde, Neha
Roschewski, Mark
Zingone, Adriana
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Mailankody, Sham
Wu, Peter
Morrison, Candis
Costello, Rene
Zhang, Yong
Burton, Debra
Mulquin, Marcia
Zuchlinski, Diamond
Lamping, Liz
Carpenter, Ashley
Wall, Yvonne
Carter, George
Cunningham, Schuyler C.
Gounden, Verena
Sissung, Tristan M.
Peer, Cody
Maric, Irina
Calvo, Katherine R.
Braylan, Raul
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Kong, Katherine A.
Weng, Li
Faham, Malek
Lindenberg, Liza
Kurdziel, Karen
Choyke, Peter
Steinberg, Seth M.
Figg, William
Landgren, Ola
JAMA ONCOLOGY, 2015, 1 (06) : 746 - 754
[4] Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, Lotfi
Dimopoulos, Meletios A.
Dispenzieri, Angela
Catalano, John
Belch, Andrew R.
Cavo, Michele
Pinto, Antonello
Weisel, Katja
Ludwig, Heinz
Bahlis, Nizar
Banos, Anne
Tiab, Mourad
Delforge, Michel
Cavenagh, Jamie
Geraldes, Catarina
Lee, Je-Jung
Chen, Christine
Oriol, Albert
de la Rubia, Javier
Qiu, Lugui
White, Darrell J.
Binder, Daniel
Anderson, Kenneth
Fermand, Jean-Paul
Moreau, Philippe
Attal, Michel
Knight, Robert
Chen, Guang
Van Oostendorp, Jason
Jacques, Christian
Ervin-Haynes, Annette
Avet-Loiseau, Herve
Hulin, Cyrille
Facon, Thierry
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10): : 906 - 917
[5] Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)
Bringhen, Sara
Antonioli, Elisabetta
Gamberi, Barbara
Bruno, Benedetto
Derudas, Daniele
Tosi, Patrizia
Fazio, Francesca
Mazza, Rita
Ronconi, Sonia
Corradini, Paolo
Lotti, Flavia
Cellini, Claudia
Falcone, Antonietta Pia
Galieni, Piero
Ria, Roberto
Belotti, Angelo
Mannina, Donato
Cafro, Anna Maria
Cangialosi, Clotilde
Vincelli, Iolanda Donatella
Lombardo, Alessandra
Larocca, Alessandra
Boccadoro, Mario
D'Agostino, Mattia
BLOOD, 2023, 142
[6] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, Jagoda K.
Kubicki, Tadeusz
Raje, Noopur
Vij, Ravi
Reece, Donna
Berdeja, Jesus
Derman, Benjamin A.
Rosenbaum, Cara A.
Richardson, Paul
Gurbuxani, Sandeep
Major, Sarah
Wolfe, Brittany
Stefka, Andrew T.
Stephens, Leonor
Tinari, Kathryn M.
Hycner, Tyler
Rojek, Alexandra E.
Dytfeld, Dominik
Griffith, Kent A.
Zimmerman, Todd M.
Jakubowiak, Andrzej J.
BLOOD, 2020, 136 (22) : 2513 - 2523
[7] CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Gay, F.
Scalabrini, D. Rota
Belotti, A.
Offidani, M.
Tacchetti, P.
Petrucci, M. T.
Pautasso, C.
Palmas, A. D.
Siniscalchi, A.
Grasso, M.
Spadano, A.
Giuliani, N.
Ballanti, S.
Patriarca, F.
Canepa, L.
Bernardini, A.
Aquino, S.
Gamberi, B.
Zambello, R.
Ledda, A.
Montefusco, V.
Omede, P.
Galli, M.
Cavo, M.
Palumbo, A.
Musto, P.
Boccadoro, M.
HAEMATOLOGICA, 2017, 102 : 143 - 144
[8] Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients
Gay, Francesca
Roeloffzen, Wilfried
Dimopoulos, Meletios A.
Rosinol, Laura
van der Klift, Marjolein
Mina, Roberto
Oriol Rocafiguera, Albert
Katodritou, Eirini
Wu, Ka Lung
Rodriguez Otero, Paula
Hajek, Roman
Antonioli, Elisabetta
van Duin, Mark
D'Agostino, Mattia
Martinez-Lopez, Joaquin
van Leeuwen-Segarceanu, Elena M.
Tacchetti, Paola
van de Donk, Niels W. C. J.
Weisel, Katja
Pour, Ludek
Radocha, Jakub
Belotti, Angelo
Schjesvold, Fredrik
Blade, Joan
Einsele, Hermann
Sonneveld, Pieter
Boccadoro, Mario
Broijl, Annemiek
BLOOD, 2023, 142
[9] Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
Tang, Wenjiao
Zhang, Li
Zheng, Yuhuan
Pan, Ling
Niu, Ting
FRONTIERS IN ONCOLOGY, 2024, 14
[10] Incidence of herpes zoster in transplant-ineligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone
Horigome, Yuichi
Kamata, Hirotoshi
Michishita, Yusuke
Yokoyama, Maki
Tadera, Noriyuki
Hayama, Kei
Suzuki, Takahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025,

← 1 2 3 4 5 →